We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

1 hedge funds and large institutions have $245 invested in ELITE PHARMACEUTICAL in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

93% less capital invested

Capital invested by funds: $3.64K → $245 (-$3.39K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
-$3.32K

ELI Hedge Fund Activity: Q4 2025 in Review

1 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2025, worth a combined $245 — down 93% from $3.64K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Ancora Advisors, exiting entirely with an estimated $3.32K sold.

  • 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q4 2025, down from 2 in Q3 2025.
  • Funds reported $245 of ELITE PHARMACEUTICAL stock for Q4 2025, down 93% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2025 and 1 closed out, a net change of -1 holder.
  • The largest ELITE PHARMACEUTICAL seller in Q4 2025 was Ancora Advisors, an estimated $3.32K sold.

Based on aggregated 13F filings for Q4 2025.